On August 15, shares of the weight loss drug concept stock, Yinno Pharmaceutical-B, opened high at 285.44%, reaching HKD 72, setting a new record for the first-day increase of new stocks this year. Each lot consists of 200 shares, and excluding transaction fees, a single lot yields a profit of HKD 10,664. The subscription multiple for this financing of Yinno Pharmaceutical reached as high as 5,364 times, surpassing the 5,257 times for Mixue Group (2097.HK) listed in early March, making it the second highest oversubscription this year with approximately 260,000 subscribers, involving about HKD 370 billion. The prospectus indicates that Yinno Pharmaceutical's core product, based on Supaglutide A, is a human-derived long-acting GLP-1 receptor agonist approved in China for the treatment of Type 2 diabetes (T2D). Recently, the trend of pharmaceutical companies listing in Hong Kong continues unabated. On August 11, Zhonghui Biotech-B officially debuted on the Hong Kong stock market, demonstrating impressive performance with an increase of over 300% within three days of listing, peaking at nearly 168.53% on its first trading day. This year, the innovative drug market in Hong Kong has been booming. Do you have confidence in the performance of innovative drug companies after their listings?